Wave life sciences announces initiation of dosing in restoraation clinical program evaluating first-ever rna editing candidate, wve-006, for alpha-1 antitrypsin deficiency

Wave life sciences announces initiation of dosing in clinical trial evaluating first-ever rna editing candidate, wve-006, in alpha-1 antitrypsin deficiency

WVE Ratings Summary

WVE Quant Ranking